Amgen's $0.46 Billion Volume Plummets 32.85% to Rank 222nd Amid Dermatology Breakthrough

On September 9, 2025, , , . The stock ranked 222nd in trading volume among listed equities.

Amgen and Kyowa Kirin Co., Ltd. released preliminary top-line results from the ASCEND Phase 3 long-term extension study evaluating rocatinlimab, an experimental therapy targeting the OX40 receptor to modulate T-cell activity in patients with moderate to severe atopic dermatitis (AD). The data, announced on the same day, highlights the potential of rocatinlimab to redefine treatment paradigms for AD, a chronic condition affecting millions globally. This development positions Amgen to strengthen its biopharmaceutical portfolio in a competitive dermatology market.

Separately, Amgen’s supply chain reported robust sales growth in Q2 2025, . However, , . These figures underscore the challenges of balancing demand for innovative therapies with profit sustainability amid economic pressures.

The ASCEND study’s outcomes could catalyze long-term therapeutic advancements in atopic dermatitis, aligning Amgen’s R&D strategy with unmet patient needs. As the company progresses toward full data analysis, the commercial potential of rocatinlimab may enhance its market position, particularly in chronic disease management segments.

To build an accurate back-test, key parameters must be defined: the stock universe (e.g., U.S.-listed equities, S&P 500), weighting methodology (equal-weighted or volume/market-cap), rebalancing frequency (daily), and inclusion of transaction costs. Clarification on these elements is required to execute the back-test effectively.